Szałapata Katarzyna, Osińska-Jaroszuk Monika, Jarosz-Wilkołazka Anna
Department of Biochemistry, Faculty of Biology and Biotechnology, Maria Skłodowska-Curie University, 19 Akademicka St., 20-033 Lublin, Poland.
Postepy Biochem. 2017;63(4):261-268.
From the earliest times, medicine has focused on finding the most suitable and effective treatment for every patient. At present, a dynamic development of diagnostic methods and techniques for designing new drugs allows to create therapies for many diseases at the molecular level. Among the many drugs appearing on the medical market every year, special attention should be paid to those whose action is based on the inhibition of proteolytic enzyme activity. Protease inhibitors are a diverse group of biologically active molecules for which antiviral, antimicrobial, antifungal, antiparasitic or anticancer effects have been documented. Successes in the treatment of HIV infection, hepatitis C and influenza diseases certainly encourage researchers to look for new inhibitors that could be used in new therapies. This paper provides an overview of selected information on enzyme inhibitors, especially protease inhibitors, which are already registered medicines and substances that are promising candidates for medical use.
从最早的时候起,医学就专注于为每位患者找到最合适、最有效的治疗方法。目前,诊断方法和新药设计技术的蓬勃发展使得在分子水平上为多种疾病开发治疗方法成为可能。在每年医药市场上出现的众多药物中,应特别关注那些作用基于抑制蛋白水解酶活性的药物。蛋白酶抑制剂是一类多样的生物活性分子,其抗病毒、抗菌、抗真菌、抗寄生虫或抗癌作用已有文献记载。在治疗艾滋病毒感染、丙型肝炎和流感疾病方面取得的成功无疑鼓励研究人员寻找可用于新疗法的新型抑制剂。本文概述了有关酶抑制剂,特别是蛋白酶抑制剂的部分信息,这些抑制剂已是注册药物以及有望用于医学的物质。